Brief: Zevra Submits EU Application for Arimoclomol to Treat Niemann-Pick Disease Type C
28/07/2025 11:04
July 28 (Reuters) - Zevra Therapeutics Inc ZVRA.O: ZEVRA THERAPEUTICS SUBMITS MARKETING AUTHORIZATION APPLICATION TO EUROPEAN MEDICINES AGENCY TO REVIEW ARIMOCLOMOL FOR THE TREATMENT OF NIEMANN-PICK DISEASE TYPE C Source text: ID:nGNXcYNGN Further company coverage: ZVRA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Zevra Therapeutics
See all newsZevra Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Zevra Therapeutics Q2 revenue rises 53% on MIPLYFFA sales
Zevra Therapeutics Inc expected to post earnings of 11 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Tenet, SLB, Digital Realty
U.S. STOCKS ON THE MOVE-Booz Allen Hamilton, Sensient, Amkor